AXSM - What's Going On Neurology-Focused Axsome Therapeutics' Stock On Monday? | Benzinga
Monday, Axsome Therapeutics Inc (NASDAQ:AXSM) released data from the SYMPHONY Phase 3 trial of AXS-12 (reboxetine) in narcolepsy patients.
Narcolepsy is a sleep disorder that makes people very drowsy during the day. People with narcolepsy find it hard to stay awake for long periods.
AXS-12 met the primary endpoint by demonstrating a substantial and statistically significant reduction from baseline in weekly cataplexy (sudden loss of muscle tone while a person is awake leads to weakness and a loss of voluntary muscle control) attacks compared to placebo at Week 5, with reductions of 83% for AXS-12 and 66% for placebo.
AXS-12 rapidly reduced weekly cataplexy attacks, demonstrating at Week 1 a reduction of 56% compared to a reduction of 31% ...